The Filing Desk

Agios Pharmaceuticals vs Nuvation Bio

Agios Pharmaceuticals AGIO · Nuvation Bio NUVB · Pharmaceuticals

Nuvation Bio reported revenue of $63 million in fiscal 2025, 1.2 times Agios Pharmaceuticals' $54 million in fiscal 2025. Agios Pharmaceuticals' revenue grew 48.0% in its latest year, and Nuvation Bio's grew 699.0%. Agios Pharmaceuticals had an operating margin of -873.9%, against -338.7% at Nuvation Bio. Free cash flow was −$377 million at Agios Pharmaceuticals and −$181 million at Nuvation Bio.

Side by side

Agios PharmaceuticalsNuvation Bio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$54M$63M
Revenue growth48.0%699.0%
Revenue growth a year, last 5 years——
Gross margin88.3%—
Operating margin−873.9%−338.7%
Net margin−764.0%−325.3%
Free cash flow−$377M−$181M
Free cash flow margin−698.3%−288.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count0.1%27.1%
Last close$31.59$3.99
P/E at the last close——
Insider trades, last 12 monthssold $4.3 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Agios PharmaceuticalsNuvation Bio
Operating margin
Percent of revenue
Agios PharmaceuticalsNuvation Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Agios PharmaceuticalsNuvation Bio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agios Pharmaceuticals and Nuvation Bio pages.